Featured Research

from universities, journals, and other organizations

Genetic Variants Put Some Patients At Risk For Particular Drug Reactions

Date:
April 3, 2002
Source:
University Of Washington
Summary:
Genetic variants in the human enzyme that metabolizes the drug warfarin, the frequently prescribed anticoagulant Coumadin, make some patients more susceptible to serious or life-threatening bleeding.

Genetic variants in the human enzyme that metabolizes the drug warfarin, the frequently prescribed anticoagulant Coumadin, make some patients more susceptible to serious or life-threatening bleeding.

In an article in the April 3, 2002, edition of the Journal of the American Medical Association, Dr. David Veenstra, assistant professor in the University of Washington School of Pharmacy, and his colleagues say that the two genetic variants, CYP2C9*2 and CTP2C9*3, are relatively common. This is one of the first studies to show an association between genetic variants and the risk of a serious adverse drug reaction.

The patients in the retrospective cohort study attended one of two anticoagulation clinics in the Seattle area and received warfarin to prevent blood clotting due to conditions such as atrial fibrillation (irregular heart rhythm).

"After we identified these patients' genotypes, we looked back at their medical records to determine if they had had severe bleeding incidents while they were taking warfarin," Veenstra said. "We looked at two specific variants in the gene for the enzyme that helps patients metabolize warfarin."

Compared to other patients, those with at least one of the genetic variants required more time to achieve stable dosing. In other words, it took a longer period of time to determine an effective and safe dose.

Additionally, patients with at least one of the two genetic variants had a significantly increased occurrence of a serious or life-threatening bleeding incident. Veenstra says that the small numbers of patients (58) with the genetic variants in the 185-person study group suggests caution in interpreting the study's results -- but that screening for these variants may allow clinicians to develop dosing protocols and surveillance techniques to reduce the risk of adverse drug reactions in warfarin patients.

"Warfarin is a very important drug for preventing blood clots," Veenstra said, "and the risk of bleeding is still quite low in patients with a variant. However, our results suggest that these patients perhaps should be started at lower warfarin doses and followed up more frequently by their clinicians."

Testing for the genetic variants is relatively straightforward, and only requires a simple blood test, Veenstra said.

Veenstra's co-investigators include Drs. Mitchell K. Higashi, L. Midori Kondo, Ann K. Wittkowsky, Sengkeo L. Srinouanprachanh, Fred M. Farin and Allan E. Rettie, all of the University of Washington. (Dr. Higashi is now with Glaxo SmithKline).

Funding for the study came from the University of Washington NIEHS Center for Ecogenetics & Environmental Health (NIEHS is the National Institute of Environmental Health Sciences), the UW's Institute for Public Health Genetics and the PhRMA Foundation.


Story Source:

The above story is based on materials provided by University Of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University Of Washington. "Genetic Variants Put Some Patients At Risk For Particular Drug Reactions." ScienceDaily. ScienceDaily, 3 April 2002. <www.sciencedaily.com/releases/2002/04/020403025604.htm>.
University Of Washington. (2002, April 3). Genetic Variants Put Some Patients At Risk For Particular Drug Reactions. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2002/04/020403025604.htm
University Of Washington. "Genetic Variants Put Some Patients At Risk For Particular Drug Reactions." ScienceDaily. www.sciencedaily.com/releases/2002/04/020403025604.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins